X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (143) 143
infectious diseases (106) 106
hiv infections - drug therapy (100) 100
male (100) 100
female (92) 92
adult (90) 90
index medicus (88) 88
middle aged (74) 74
immunology (72) 72
antiretroviral therapy (59) 59
hiv (53) 53
virology (53) 53
anti-hiv agents - therapeutic use (51) 51
hiv infection (48) 48
hiv infections - complications (40) 40
hiv infections - virology (38) 38
human immunodeficiency virus--hiv (38) 38
protease inhibitors (38) 38
pharmacology & pharmacy (36) 36
microbiology (35) 35
risk factors (34) 34
treatment outcome (33) 33
anti-hiv agents - adverse effects (32) 32
drug therapy (30) 30
cd4 lymphocyte count (29) 29
tenofovir (29) 29
antiretroviral drugs (28) 28
viral load (27) 27
aids/hiv (26) 26
aids (25) 25
anti-hiv agents - administration & dosage (25) 25
hiv infections - immunology (24) 24
cross-sectional studies (23) 23
hiv-1-infected patients (23) 23
therapy (23) 23
antiretroviral therapy, highly active (22) 22
hiv-infected patients (22) 22
prospective studies (22) 22
drug therapy, combination (21) 21
hiv patients (21) 21
hiv protease inhibitors - therapeutic use (21) 21
efficacy (20) 20
human immunodeficiency virus (20) 20
adenine - analogs & derivatives (19) 19
clinical trials (19) 19
osteoporosis (19) 19
ritonavir - therapeutic use (19) 19
active antiretroviral therapy (18) 18
antiretrovirals (18) 18
health aspects (18) 18
hiv-1 (18) 18
hiv-1 - drug effects (18) 18
medicine (17) 17
aged (16) 16
efavirenz (16) 16
highly active antiretroviral therapy (16) 16
pilot projects (16) 16
research (16) 16
antiretroviral agents (15) 15
drug administration schedule (15) 15
patients (15) 15
prevalence (15) 15
reverse transcriptase inhibitors - therapeutic use (15) 15
care and treatment (14) 14
dosage and administration (14) 14
ritonavir (14) 14
ritonavir - administration & dosage (14) 14
toxicity (14) 14
adenine - therapeutic use (13) 13
antiviral agents (13) 13
human-immunodeficiency-virus (13) 13
immunodeficiency-virus-infection (13) 13
retrospective studies (13) 13
antiretroviral therapy, highly active - methods (12) 12
bone density (12) 12
disease (12) 12
hiv infections - epidemiology (12) 12
hiv protease inhibitors - adverse effects (12) 12
hiv-infection (12) 12
lipodystrophy (12) 12
nevirapine (12) 12
quality of life (12) 12
research article (12) 12
risk (12) 12
safety (12) 12
time factors (12) 12
analysis (11) 11
anti-hiv agents - pharmacokinetics (11) 11
cd4 antigen (11) 11
darunavir (11) 11
hiv infections - blood (11) 11
infection (11) 11
lipids (11) 11
protease inhibitor (11) 11
rna, viral - blood (11) 11
tenofovir disoproxil fumarate (11) 11
adherence (10) 10
antiretroviral therapy, highly active - adverse effects (10) 10
cohort studies (10) 10
follow-up studies (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, p. e0168426
Journal Article
BioMed Research International, ISSN 2314-6133, 2016, Volume 2016, pp. 4380845 - 5
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 5/2010, Volume 50, Issue 9, pp. 1300 - 1308
Journal Article
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2009, Volume 53, Issue 5, pp. 1937 - 1943
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
IN-VITRO | HIV | DIDANOSINE | CARBOVIR TRIPHOSPHATE | REVERSE-TRANSCRIPTASE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | P-GLYCOPROTEIN EXPRESSION | LOPINAVIR/RITONAVIR | BLOOD MONONUCLEAR-CELLS | PROTEASE INHIBITORS | MASS-SPECTROMETRY | Lamivudine - administration & dosage | Area Under Curve | Humans | Middle Aged | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Drug Therapy, Combination | Dideoxynucleosides - administration & dosage | Adenine - analogs & derivatives | Cross-Sectional Studies | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Lopinavir | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Lamivudine - pharmacokinetics | Adenine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Dideoxynucleosides - pharmacokinetics | Organophosphonates - administration & dosage | Pilot Projects | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Longitudinal Studies | Index Medicus | Pharmacology
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e114142
Background: HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to... 
CONTROLLED-TRIAL | ACTIVATION | CD4 | T-CELL RECOVERY | MULTIDISCIPLINARY SCIENCES | ANTIRETROVIRAL THERAPY | MICROBIAL TRANSLOCATION | SIV INFECTION | RALTEGRAVIR INTENSIFICATION | PROTEASE INHIBITORS | D-DIMER | HIV Infections - blood | Prospective Studies | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Raltegravir Potassium - therapeutic use | Male | Biomarkers - blood | HIV Integrase Inhibitors - administration & dosage | Inflammation - blood | HIV Infections - immunology | HIV Integrase Inhibitors - therapeutic use | Adult | Female | HIV Infections - drug therapy | Usage | HIV patients | Inflammation | T cells | HIV (Viruses) | Infection | Highly active antiretroviral therapy | Protease inhibitors | Proteases | Analysis | Hepatitis C virus | Health aspects | HIV infection | Antiretroviral drugs | Composition | CD8 antigen | Markers | Lymphocytes T | Proteinase inhibitors | T cell receptors | Infections | Patients | Antiretroviral therapy | CD4 antigen | Amplification | Cell activation | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Antiretroviral agents | Integrals | Human immunodeficiency virus--HIV | Replication | Sampling methods | Plasma levels | Dimers | Antiretrovirals | HIV infections | Inflamació | Marcadors bioquímics | Infeccions per VIH | Biochemical markers | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, p. e84676
Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy... 
REVERSE-TRANSCRIPTASE INHIBITOR | IMMUNODEFICIENCY-VIRUS-INFECTION | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | MULTIDISCIPLINARY SCIENCES | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | HDL-CHOLESTEROL | LIPID PROFILES | ANTIRETROVIRAL TREATMENT | TREATMENT-NAIVE PATIENTS | HIV Protease Inhibitors - adverse effects | Drug Administration Schedule | HIV Infections - epidemiology | HIV Infections - virology | Humans | Middle Aged | Male | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Patient Satisfaction | HIV Infections - immunology | Lipids - blood | Pyridazines - administration & dosage | Adult | Female | HIV Infections - drug therapy | Pyridazines - adverse effects | Pyridazines - therapeutic use | Highly active antiretroviral therapy | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | Patient satisfaction | T cells | HIV (Viruses) | HIV infection | Slopes | Antiretroviral drugs | Diarrhea | Lymphocytes T | Triglycerides | Proteinase inhibitors | Patients | Cholesterol | Switching | CD4 antigen | Randomization | Motivation | Acquired immune deficiency syndrome--AIDS | Protease | Antiretroviral agents | Human immunodeficiency virus--HIV | Failure analysis | Mutation | Placebo-controlled trial | Tractament | HDL-cholesterol | Lipid profiles | VIH (Virus) | Research | Double-blind | Ciències de la salut | Reverse-transcriptase inhibitor | Treatment-naive patients | Virus-induced immunosuppression | Experienced HIV-1-infected patients | Immunodeficiency-virus-infection | TMC125 etravirine | Àrees temàtiques de la UPC | Antiretroviral treatment | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article
EBioMedicine, ISSN 2352-3964, 03/2016, Volume 5, Issue C, pp. 135 - 146
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2015, Volume 61, Issue 3, pp. 403 - 408
Journal Article
JAIDS : Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 2005, Volume 38, Issue 5, pp. 560 - 565
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e107625
Journal Article